Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39106

Title:	Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
Authors:	Vansteenkiste, J. F. Demedts, I. Pons-Tostivint, E. Biesma, B. Borm, F. Colinet, B. CUPPENS, Kristof Derijcke, S. Greillier, L. Juergens, J. Moro-Sibilot, D. Perol, M. Sebastian, M. Skrzypski, M. Theelen, W. Van De Kerkhove, C. Collodoro, M. Plumas, J. Debruyne, C. Sibille, A.
Issue Date:	2022
Publisher:	ELSEVIER
Source:	ANNALS OF ONCOLOGY, 33 (7) , p. S1086 (Art N° 1176P)
Document URI:	http://hdl.handle.net/1942/39106
ISSN:	0923-7534
e-ISSN:	1569-8041
DOI:	10.1016/j.annonc.2022.07.1299
ISI #:	000866211601438
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
1176PO~1.PDF Restricted Access	Published version	85.34 kB	Adobe PDF	View/Open Request a copy

Check